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(difference: 1±1%). The planned mean bladder dose (18.4 Gy) 




Conclusion: For the membranous urethra, rectum, and anus, 
the dose in the repeat CTs was higher than was planned. This 
warrants future research investigating whether increased 
dose leads to increased incidence of side effects and whether 
dose increases should be mitigated by treatment adaptations. 
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Purpose or Objective: Endpoints for this ethically approved 
clinical study:  
- Assess the feasibility of planning SABR for low-intermediate 
risk prostate cancer using flattening filter free volumetric arc 
therapy.  
- Assess safety of treatment delivery by recording RTOG 
scoring criteria of acute gastro-intestinal (GI) and genito-
urinary (GU) toxicity. 
 
Material and Methods: 25 patients were included, each has 
18 week toxicity data.  
Inclusion criteria: 
Written informed consent, 18 - 80 years, T1-T2 stage, WHO 
performance status ≤ 2. Initial PSA ≤ 20 ng/ml. Gleason score 
≤7 with histologically-proven prostate adenocarcinoma. No 
pathologic lymph nodes on CT/ MRI scans and no distant 
metastases. No previous prostate surgery, including 
transurethral resection of the prostate no TURP in past 6 
months. No previous active malignancy within the last 10 
years.  
A prescription dose of 35Gy in 5 fractions was treated 
alternate days. This was planned using Rapidarc VMAT 
planning on Varian Eclipse (V.10), treated using a Varian 
Truebeam STX.  
A clinically acceptable plan was determined by assessing the 
planned dose to GTV/PTV criteria and achieving dose 
constraints (table 1).  
 
GI, GU and skin toxicity was scored using Radiation therapy 
oncology group (RTOG) criteria. Baseline data was recorded 
before treatment commenced (baseline), week 4 and week 
18. 
 
Results: Results include first 25 patients.  
Age range was 52-78, median 70, initial PSA median 4.3-29.2, 
median 10.8ng/ml. All patients were successfully planned 
and treated with VMAT-FFF with plans being deemed 
clinically acceptable for 100% of patients.  
GU and GI toxicity at baseline, week 4 and week 18 is 
detailed for each grade below, respectively.  
GU toxicity: 
Grade 0 - 44%, 12%, 48%  
Grade 1 - 52%, 56%, 48%  
Grade 2 – 4%, 28%, 4%  
Grade 3 – 0%, 4%, 0%  
For GU toxicity, a statistically significant increase in toxicity 
was observed from baseline to week 4 (p=<0.01) and a 
significant reduction from week 4 to week 18 (p=<0.01). No 
significant difference was observed between baseline and 
week 18, with toxicity reducing to similar levels as baseline.  
GI toxicity (baseline, week 4, week 18): 
Grade 0 – 96%, 52%, 72%  
Grade 1 – 4%, 40%, 28%  
Grade 2 – 0%, 8%, 0%  
Grade 3 – 0%,0%, 0%  
GI toxicity significantly increased from baseline to week 4 
(p=<0.01). From week 4 to week 18, toxicity had reduced 
(p=<0.05). A significant difference was observed between 
baseline and week 18 (p=<0.05) with toxicity having reduced, 
but not having returned to baseline grade. 
 
Conclusion: Highly conformal plans were created for all 
patients. Toxicity was acceptable throughout, with toxicity 
at week 18 reducing to that of baseline for GU toxicity, and 
reducing significantly for GI toxicity. 1 patient experienced 
grade 3 GU toxicity at week 4, this resolved by week 10. 
Longer follow-up is required to assess late outcomes. 
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Purpose or Objective: To investigate the feasibility of single 
fraction High Dose Rate (HDR) brachytherapy (BT) as 
monotherapy for low risk prostate cancer. 
 
Material and Methods: CT scans of 30 patients were selected 
from our prostate HDR database. Patients were divided in 
groups based on prostate volume (< 40cc, 40-70cc and >70cc) 
and the number of needles used (13-16 and 17-22). The 
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existing needle geometry was used to regenerate new 
treatment plans for three radiation schemes: 1x19.0Gy, 
1x19.5Gy and 1x20Gy. All plans were optimized according to 
the following objectives: 
Prostate V100% ≥ 95% Prostate D90% ≥ 100% 
Bladder D1cc < 16.0 Gy Bladder D2cc < 15.5 Gy  
Rectum D1cc < 15.5 Gy Rectum D2cc < 14.5 Gy Rectum V100% 
0 cc 
Urethra D0,1cc < 21.0 Gy Urethra D10% < 20.5 Gy Urethra 
V120% 0 cc 
A total of 90 plans were generated using an inverse planning 
module. The planning target volume (PTV) was the prostate 
without margins. The coverage of the prostate was 
maximized considering the dose constraints for the organs at 
risk (OAR). The primary end point of this study was the 
feasibility of above mentioned target coverage and OAR 
constraints. The secondary end point was to investigate the 
restricting factors to reach a feasible plan stratified to 
prostate volume, OAR position and implant geometry. 
 
Results: The average prostate V100% for the 19.0, 19.5 and 
20.0Gy schemes was 96.6%, 95.3% and 93.0% respectively 
with 83%, 57% and 33% of plans meeting this objective. The 
D90% of the prostate averaged 20.3 Gy , 20.3 Gy and 20.4 Gy 
respectively. Only 4 plans failed this objective. 
The 40-70cc group showed an average prostate V100% of 
96.3% an increase of 2.1% and 2.7% compared to the < 40cc 
and >70cc group respectively.  
The number of needles had no influence on prostate coverage 
and urethra constraints. The rectum and bladder D1cc and 
D2cc increased for the 17-22 needle group with 5.7%, 8.6% 
and 3.3%, 5.3% respectively.  
The average prostate V100% decreased in patients with a 
larger distance between the urethra and the posterior border 
of the prostate. 
Prostate V100% increased from 95.7% to 97.5% in patients 
with a prostate to rectum distance of 2mm or more. 
 
Conclusion: Single fraction HDR brachytherapy as 
monotherapy in patients with prostate cancer is feasible 
using our current implant geometry. Considering the OAR 
constraints, an acceptable D90% was reached in 96% of 
plans.Prostate volume, implant geometry and OAR proximity 
have a substantial impact on target coverage. 
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Purpose or Objective: To evaluate the feasibility of 
automated single arc treatment planning for prostate cancer 
patients using a commercially available treatment planning 
system. We also compared the resultant AutoplanningTM 
plans with our current institutional inverse planned 
prostates. 
 
Material and Methods: A technique was created within the 
AutoplanningTM module of the PinnacleTM treatment 
planning system using institutional prescription 
dose/fractionation and OAR constraints to be delivered with 
a single arc VMAT plan. The Planning Target Volume PTV1 
(74Gy) encompasses the prostate; PTV2 (66.6Gy) 
encompasses the prostate and the base or full seminal 
vesicles plus setup margins both delivered simultaneously in 
37 fractions. Plans were generated for 10 randomly selected 
patients with prostate cancer treated at our institution, using 
the automated treatment technique template. Plan quality 
was assessed using institutional criteria and ICRU 83 criteria: 
D98, D2, Conformity Index (CI), Homogeneity Index (HI) and 
Remaining Volume at Risk (RVR). OAR constraints for rectum 
D65<30%, Bladder D50<50%, Femoral Heads, D50< 50%. Bowel 
D50<50cc, D55<14cc and D60< 1cc were assessed. The time 
for planning was also documented. 
The ten AutoplanningTM technique plans were compared with 
clinical institutional VMAT prostate plans in a blinded study. 
Plans were compared by Clinical Oncologists, assessing 
clinical coverage of the PTVs, OAR sparing and DVH 
parameters. 
 
Results: Table 1 summarises results of the automated plan 
generation. The automated technique produced highly 
conformal plans that met institutional clinical constraints for 
7 of 10 plans in a single run. In the 3 cases that failed, 
overlap of the PTV with rectum or bowel exceeded 
institutional DVH goals (Fig 1). There were no significant 
differences between the two planning techniques when 
comparing CI and HI. 
 




Fig 1. Impact of PTV overlap on Mean OAR doses for 
automated planning technique. 
 
Conclusion: The automated technique for VMAT planning for 
prostate cancer is a promising solution which is feasible and 
may improve efficiency by automating cases that meet 
institutional dose volume constraints. We will present the 
results of the blinded plan selection study at the meeting.  
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